Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.46), $0.05 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $16.95 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Proto Labs (PRLB) PT Raised to $91 at Benchmark on Meeting and Exceeding Previous Target
• Incyte acquires Vega Therapeutics for $1.25B upfront